VX-222 (S1480; VCH-222)

Min.Order / FOB Price:Get Latest Price

1 Gram	Negotiable

1 Gram

Negotiable

Min.Order :1 Gram
Purity: ≥98%

Keywords

VX-222 S1480 VCH-222

Quick Details

Appearance:
Application:For laboratory use only- not intended for drug manufacturing, not for household, human or animal consumption
PackAge:
ProductionCapacity:1|Kilogram|Quarter
Storage:-20℃
Transportation:by air

Superiority:

We are a CRO company, and our Research and Development team is consisted of PhDs and Masters in chemistry and pharmacy.

We are committed to protect our customer’s privacy with the highest level of ethical standard. Our dedicated team will follow up on every order and provide instant feedback on the status to our customer.

We stand behind our product by providing a complete QA report. The test data of customer order can be provided upon request.

We make our efforts to offer customer innovative, customized, high-quality service.

Our custom manufacturing encompasses everything from pharmaceutical intermediates to API.

Details:

VX–222 (VCH–222) is a novel, potent and selective inhibitor of HCV polymerase with IC50 of 0.94–1.2 μM, 15.3–fold less effective for mutant M423T, and 108–fold less effective for mutant I482L. IC50 Value: 0.94 μM (HCV NS5B 1a); 1.2 μM (HCV NS5B 1b) Target: HCV VX–222 is a small molecule non–nucleoside inhibitor of HCV NS5B polymerase that is being investigated for the treatment of hepatitis C virus infection. VX–222 exhibits non–competitive and selective inhibition in HCV NS5B of genotype 1a and 1b, with IC50 of 0.94 and 1.2 μM, respectively. VX–222 selectively inhibits the replication of subgenomic HCV genotype 1a and 1b with an EC50 of 22.3 and 11.2 nM, respectively. Similarly, a recent study shows that VX–222 inhibits the 1b/Con1 HCV subgenomic replicon, with an EC50 of 5 nM. In rats and dogs, VCH–222 displays fine pharmacokinetic pro le, including low total body clearance and excellent oral bioavailability (greater than 30%) and good ADME properties. VCH–222 is biotransformed by several enzymes (CYP1A1, 2A6, 2B6, 2C8, CYP 3A4, UGT1A3) and is predicted to be actively transported in liver and excreted mainly intact in bile or as glucuronide adducts.

View All